Ehsan Rahimy, David Sarraf. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AdultAngiogenesis Inhibitors/administration & dosageAngiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal, Humanized/administration & dosageAntibodies, Monoclonal, Humanized/therapeutic useAstrocytoma/drug therapyAstrocytoma/surgeryBevacizumabBrain Neoplasms/drug therapyBrain Neoplasms/surgeryEstrogen Antagonists/adverse effectsHumansIntravitreal InjectionsMacular Edema/chemically inducedMacular Edema/diagnosisMacular Edema/drug therapyMaleRetinal Diseases/chemically inducedRetinal Diseases/diagnosisRetinal Diseases/drug therapyTamoxifen/adverse effectsTomography, Optical CoherenceVascular Endothelial Growth Factor A/antagonists & inhibitorsVisual Acuity/physiology
Substances: See more » Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedEstrogen AntagonistsVEGFA protein, humanVascular Endothelial Growth Factor ATamoxifenBevacizumab
Year: 2012 PMID: 22776935 DOI: 10.1001/archophthalmol.2011.2741
Source DB: PubMed Journal: Arch Ophthalmol ISSN: 0003-9950